Angielski
Chronic hepatitis C infection (HCV) has been a global health burden since its discovery in 1989. This is the integrated reference book for all clinicians, researchers, and students dealing with HCV infection. Sofosbuvir is a backbone for the majority of direct-acting antivirals (DAA) combination regimens for all HCV Genotypes infected patients. This is the first book that offers a concise and up-to-date review on Sofosbuvir including pharmacological profile and difficult-to-treat-specific populations such as cirrhotic patients, HCV Co-infection (HIV and/or hepatitis B infection), renal impairment, renal and liver transplant, hepatocellular cancer, previous treatment failure, psychiatric illness, and substance abuse. The book also addresses evolving therapy, and future directions in the antiviral treatment of hepatitis C. Clinicians, residents, students, and physician assistants who like a prompt review of hepatitis C treatment and new developments in treatment for hepatitis C will receive the greatest advantage from this concise guide. Based on promising results from the previous and ongoing studies involving sofosbuvir; HCV will likely be the first chronic viral infection to be eradicated globally with combinations of DAA. The authors, editors, and publishers have exerted every effort to ensure that drug selections and dosage outlined in this text are per current recommendations for hepatitis C treatment and practice at the time of publication.
